198 related articles for article (PubMed ID: 26496320)
41. Zoledronic acid: a review of its use in breast cancer.
Lyseng-Williamson KA
Drugs; 2008; 68(18):2661-82. PubMed ID: 19093706
[TBL] [Abstract][Full Text] [Related]
42. Patient management, and time and health care resource utilization associated with the use of intravenous bisphosphonates for patients with metastatic bone disease: a Delphi study.
Xie F; Hopkins R; Burke N; Tarride JE; Goeree R
Hosp Pract (1995); 2012 Apr; 40(2):131-7. PubMed ID: 22615087
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and safety of denosumab versus zoledronic acid in patients with bone metastases: a systematic review and meta-analysis.
Sun L; Yu S
Am J Clin Oncol; 2013 Aug; 36(4):399-403. PubMed ID: 22772430
[TBL] [Abstract][Full Text] [Related]
44. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
[TBL] [Abstract][Full Text] [Related]
45. Use of intravenous bisphosphonates in older women with breast cancer.
Giordano SH; Fang S; Duan Z; Kuo YF; Hortobagyi GN; Goodwin JS
Oncologist; 2008 May; 13(5):494-502. PubMed ID: 18515734
[TBL] [Abstract][Full Text] [Related]
46. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
47. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
48. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (alliance).
Smith MR; Halabi S; Ryan CJ; Hussain A; Vogelzang N; Stadler W; Hauke RJ; Monk JP; Saylor P; Bhoopalam N; Saad F; Sanford B; Kelly WK; Morris M; Small EJ
J Clin Oncol; 2014 Apr; 32(11):1143-50. PubMed ID: 24590644
[TBL] [Abstract][Full Text] [Related]
49. Risk of skeletal-related events in patients with advanced prostate cancer treated with pamidronate or zoledronic acid.
Spence MM; Hui RL; Chan J; Schottinger JE
Ann Pharmacother; 2010 Sep; 44(9):1384-8. PubMed ID: 20682850
[TBL] [Abstract][Full Text] [Related]
50. Zoledronic acid: past, present and future roles in cancer treatment.
Saad F
Future Oncol; 2005 Apr; 1(2):149-59. PubMed ID: 16555985
[TBL] [Abstract][Full Text] [Related]
51. Zoledronic acid and clodronate in the treatment of malignant bone metastases with hypercalcaemia; efficacy and safety comparative study.
Sabry NA; Habib EE
Med Oncol; 2011 Jun; 28(2):584-90. PubMed ID: 20204542
[TBL] [Abstract][Full Text] [Related]
52. Zoledronic acid : a review of its use in the management of bone metastases of malignancy.
Dhillon S; Lyseng-Williamson KA
Drugs; 2008; 68(4):507-34. PubMed ID: 18318568
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
McKay RR; Lin X; Perkins JJ; Heng DY; Simantov R; Choueiri TK
Eur Urol; 2014 Sep; 66(3):502-9. PubMed ID: 24613250
[TBL] [Abstract][Full Text] [Related]
54. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Brown JE; Cook RJ; Lipton A; Coleman RE
Clin Cancer Res; 2012 Nov; 18(22):6348-55. PubMed ID: 22952345
[TBL] [Abstract][Full Text] [Related]
55. Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.
Lipton A; Cook R; Saad F; Major P; Garnero P; Terpos E; Brown JE; Coleman RE
Cancer; 2008 Jul; 113(1):193-201. PubMed ID: 18459173
[TBL] [Abstract][Full Text] [Related]
56. Meta-analysis comparing denosumab and zoledronic acid for treatment of bone metastases in patients with advanced solid tumours.
Zheng GZ; Chang B; Lin FX; Xie D; Hu QX; Yu GY; Du SX; Li XD
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 27430483
[TBL] [Abstract][Full Text] [Related]
57. Bisphosphonates in the treatment of skeletal metastases.
Conte P; Coleman R
Semin Oncol; 2004 Oct; 31(5 Suppl 10):59-63. PubMed ID: 15490377
[TBL] [Abstract][Full Text] [Related]
58. Electrolyte abnormalities with zoledronic acid therapy.
Sorscher SM
Cancer J; 2002; 8(4):348; author reply 348-9. PubMed ID: 12184414
[No Abstract] [Full Text] [Related]
59. Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy.
Harvey HA
Semin Oncol; 2004 Dec; 31(6 Suppl 12):23-30. PubMed ID: 15719598
[TBL] [Abstract][Full Text] [Related]
60. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
Maxwell C; Swift R; Goode M; Doane L; Rogers M
Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
